# ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure

> **NCT03416270** · PHASE2 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 34 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus
- Heart Failure

## Interventions

- **DRUG:** Ertugliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03416270
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-28
- **Primary completion:** 2021-04-14
- **Final completion:** 2021-04-14
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2025-05-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03416270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03416270, "ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03416270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*